source
- AstraZeneca’s ATTR-CM Silencer Trial Fails to Show Benefit Over Existing Stabilizer TherapyAstraZeneca announced that its Phase 3 trial of a silencer drug for transthyretin amyloid cardiomyopathy (ATTR-CM) did not meet its primary endpoints. The study showed no additional clinical benefi…
- AusperBio secures $120 million Series C to push hepatitis B antisense therapy into Phase 3AusperBio Therapeutics announced it has closed a $120 million Series C financing round aimed at moving its hepatitis B antisense oligonucleotide candidate toward late‑stage trials and eventual mark…